Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
What the film says
B-cell lymphoma is treatable, often curable, until it comes back. Then engineered CAR T cells changed everything. But they are built from each patient's own cells, take weeks, and fail in nearly half of those who get them.
The idea: an immune cell you can take off the shelf, and two antibodies to aim it.
Natural killer cells from a healthy donor are grown and infused weekly for three weeks. Alongside them, rituximab and tafasitamab coat the lymphoma cells, each grabbing a different surface marker. Coated cells are exactly what natural killer cells are built to destroy.
This trial, in Cleveland with Paolo Caimi and George Deng, is the first test of the combination, asking what dose is safe. Public record; not medical advice.
Sources behind this film
Treatable, often curable, until relapse; >80,000 US cases and ~20,000 deaths a year; CAR T changed relapsed lymphoma but is autologous, slow to make, and relapses occur in 40–60%; Donor NK cells infused weekly for three weeks; IL-2; lymphodepletion; Rituximab (CD20) and tafasitamab (CD19) coat lymphoma cells; NK cells kill antibody-coated cells (+1 more lines)
Salles G. Lancet Oncol, 2020
Rituximab (CD20) and tafasitamab (CD19) coat lymphoma cells; NK cells kill antibody-coated cells
The drug
Tafasitamab is dosed at 12 mg/kg and given intravenously (IV) weekly for 3 weeks on Days 0,7,14).
Allogeneic NK cells are given intravenously (IV) weekly for 3 weeks on Days 0, 7, 14. Dose escalation will be conducted using a Bayesian optimal interval (BOIN) design starting at dose level 1 (500 x 106 cells) and proceeding to dose level 2 (1,000 x 106 cells) if criteria are met.
More than 80,000 cases of non-Hodgkin lymphoma (NHL) are diagnosed each year in the United States (US), with nearly 20,000 people dying from this group of diseases annually. There are several subgroups of NHL, with the B cell lymphomas being much more common than T-cell lymphomas.
The study
This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
NK cells are an investigational (experimental) treatment which means they are not approved by the Food and Drug Administration (FDA). NK cells are a type of lymphocyte that's part of the body's natural immune system, and they can kill cancer cells by creating pores in the cancer cell membranes and inducing apoptosis (programmed cell death).
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.